Patenting in the European medical nutrition industry: Trends, opportunities and strategies

Weenen, Tamar; Pronker, Esther; Commandeur, Harry; Claassen, Eric

doi:10.1016/j.phanu.2012.10.003

Cited by 19 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, they were able to recommend increased R&D funding for the technology to accelerate development (Chen et al, 2011). Similarly, Weenen et al (2013) [38] examined medical nutrition patent data and showed that the medical nutrition industry is currently in the growth stage (Figure 2), indicating ample future innovation opportunities.…”

Section: Technological Lifecyclesmentioning

confidence: 94%

“…It is generally presumed that a technology follows a cer-tain pattern throughout its lifecycle. The technology saturation-curve (S-curve) method of analysis has been described and employed to retrieve information on the lifecycle phase of a given technology (Figure 2) [37,38]. The technology S-curve can be illustrated by means of a certain technology's cumulative patent count against time or R&D expenditures.…”

Section: Technological Lifecyclesmentioning

confidence: 99%

“…The former refers to patents that have been cited by the patent in consideration [42]. This is an indicator of preceding knowledge and the average number of backward citations has proven to be invertly related to the radicalness of the respective invention; lower numbers of backward citations are associated with more radical inventions [38]. Forward citations refer to the frequency with which a particular patent is cited by newer patent applications.…”

Section: Patent Citation Analysismentioning

confidence: 99%

See 2 more Smart Citations

Limits of Biotechnological Innovation

Fernald¹,

Weenen²,

Sibley³

et al. 2013

View full text Add to dashboard Cite

During the past two decades the biopharmaceutical industry has been facing an innovation deficit, characterized by increasing research & development costs and stagnant productivity. From its inception, biotechnology has been expected to counter this deficit by its revolutionary science-based approach to drug discovery. For this study we gathered patent and product data related to the technological development of the first two biotechnologies: recombinant DNA technology and monoclonal antibody technology. We studied the technological lifecycles of these technologies in terms of scientific discoveries and inventions as well as product innovations. Results indicate that over the years inventions related to these technologies have simultaneously become less radical and less valuable. Furthermore, our analysis shows that these biotechnologies have reached a stage of technological limit or saturation, which may be followed by an innovation cliff. Now, more than ever, it is crucial to examine new strategies and opportunities for value creation, capturing, and delivery, within the biopharmaceutical industry

show abstract

Section: Technological Lifecyclesmentioning

confidence: 94%

Section: Technological Lifecyclesmentioning

confidence: 99%

Section: Patent Citation Analysismentioning

confidence: 99%

See 1 more Smart Citation

Limits of Biotechnological Innovation

Fernald¹,

Weenen²,

Sibley³

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Patents are highly valuable mechanisms for protecting innovations. They provide important competitive advantages, such as the invention right of for twenty years (Weenen et al 2013). In addition, patents are considered good indicators of the technological innovation process (Hidalgo-Nuchera, Iglesias-Pradas, and Hernández-García 2009; Rodríguez and Tello 2012 utilization).…”

Section: Scientometric Patent Analysismentioning

confidence: 99%

Major advances in ophthalmology: emergence of bio-additive manufacturing

Salvador¹,

Menéndez²

2016

JISIB

View full text Add to dashboard Cite

Important efforts to discover new ways to combat illnesses are being carried outworldwide. In this sense, bio-additive manufacturing is an innovative technology that willrevolutionize the health industry, as it provides the possibility to develop three-dimensional biodevices, such as body tissues and even organs. This research explores the most novel inventionsof bio-additive manufacturing in ophthalmology. The main aim is to support the decisionmaking of the research community and the organizations involved in this industry. The majoradvances, organizations, research focuses and main countries involved in the ophthalmologyfield were identified. To accomplish this, a scientometric patent analysis was carried out usingadvanced data mining software and consultations with experts. Insights show a global researchtrend toward the development of lenses, followed by prosthesis and implants. Bio-additivemanufacturing is now in a nascent S-curve phase; however, important advances are beingcarried out.

show abstract

“…This offers a large market opportunity which is being seized with a large patent portfolio (Abramson 2011). However, probiotics are increasingly gaining health applications (Weenen et al 2013), supported by major advances in the identification and characterization of microbes (O'Callaghan et al 2016). Some of these health applications include disbyosis, intestinal diseases of mammals, among others (Foligné et al 2013;Banan-Mwine Daliri et Lee 2015).…”

Section: Introductionmentioning

confidence: 99%

The combination of the disciplines of Techmining and semantic TRIZ for better and faster analyzing technology evolution

Vicente-Gomila¹,

Miguel²

View full text Add to dashboard Cite

Patenting in the European medical nutrition industry: Trends, opportunities and strategies

Cited by 19 publications

References 23 publications

Limits of Biotechnological Innovation

Limits of Biotechnological Innovation

Major advances in ophthalmology: emergence of bio-additive manufacturing

The combination of the disciplines of Techmining and semantic TRIZ for better and faster analyzing technology evolution

Contact Info

Product

Resources

About